.avp-product {
–c: #00c8ff;
–c2: #8ff1ff;
–ink: #07121f;
–ink2: #0a1526;
–line: rgba(0,200,255,.18);
–text: #eaf6ff;
–muted: rgba(234,246,255,.78);
–bg: #f3f7fc;
–inkText: #06101c;
font-family: Inter, system-ui, -apple-system, BlinkMacSystemFont, “Segoe UI”, sans-serif;
background: var(–bg);
color: var(–inkText);
max-width: 1180px;
margin: 34px auto;
padding: 0 18px 40px;
}.avp-hero {
border-radius: 26px;
background: radial-gradient(1200px 260px at 14% -60%, rgba(0,200,255,.22), transparent 60%), linear-gradient(180deg, var(–ink), var(–ink2));
border: 1px solid var(–line);
box-shadow: 0 22px 70px rgba(0,0,0,.18);
padding: 24px;
margin-bottom: 20px;
}.avp-hero-kicker {
display: inline-flex;
align-items: center;
gap: 10px;
font-size: 11px;
letter-spacing:.22em;
text-transform: uppercase;
font-weight: 900;
color: var(–c2);
margin-bottom: 12px;
}.avp-hero-led {
width: 8px;
height: 8px;
border-radius: 999px;
background: var(–c);
box-shadow: 0 0 18px rgba(0,200,255,.65);
}.avp-hero h1 {
margin: 0 0 12px;
font-size: clamp(28px, 5vw, 42px);
font-weight: 800;
color: #fff;
line-height: 1.15;
}.avp-hero-tagline {
color: var(–muted);
font-size: 15px;
margin-bottom: 22px;
max-width: 600px;
}.avp-hero-stats {
display: grid;
grid-template-columns: repeat(auto-fit, minmax(130px, 1fr));
gap: 14px;
margin-bottom: 22px;
}.avp-stat {
background: rgba(0,200,255,.08);
border: 1px solid var(–line);
border-radius: 14px;
padding: 16px;
text-align: center;
}.avp-stat-value {
font-size: 22px;
font-weight: 800;
color: var(–c);
display: block;
}.avp-stat-label {
font-size: 11px;
text-transform: uppercase;
letter-spacing:.08em;
color: var(–muted);
margin-top: 4px;
display: block;
}.avp-stat-note {
font-size: 10px;
color: rgba(143,241,255,.6);
margin-top: 2px;
display: block;
}.avp-hero-trust {
display: flex;
flex-wrap: wrap;
gap: 10px;
}.avp-trust-pill {
background: rgba(0,200,255,.12);
border: 1px solid var(–line);
border-radius: 999px;
padding: 8px 16px;
font-size: 12px;
font-weight: 600;
color: var(–c2);
}.avp-preorder-banner {
background: linear-gradient(135deg, rgba(0,200,255,.15), rgba(143,241,255,.08));
border: 1px solid var(–c);
border-radius: 14px;
padding: 16px 22px;
margin-bottom: 22px;
display: flex;
align-items: center;
gap: 14px;
}.avp-preorder-badge {
background: var(–c);
color: #000;
font-size: 11px;
font-weight: 800;
text-transform: uppercase;
letter-spacing:.12em;
padding: 6px 14px;
border-radius: 999px;
white-space: nowrap;
}.avp-preorder-text {
color: var(–c2);
font-size: 14px;
font-weight: 600;
}.avp-section {
background: #fff;
border-radius: 20px;
padding: 28px;
margin-bottom: 18px;
border: 1px solid rgba(0,30,60,.08);
box-shadow: 0 4px 20px rgba(0,30,60,.04);
}.avp-section h2 {
font-size: 20px;
font-weight: 700;
color: var(–ink);
margin: 0 0 18px;
padding-bottom: 12px;
border-bottom: 2px solid var(–c);
display: inline-block;
}.avp-section h3 {
font-size: 16px;
font-weight: 700;
color: var(–ink);
margin: 22px 0 12px;
}.avp-section p {
line-height: 1.7;
color: #334155;
margin: 0 0 14px;
}.avp-section ul {
margin: 0 0 14px;
padding-left: 20px;
}.avp-section li {
line-height: 1.7;
color: #334155;
margin-bottom: 8px;
}.avp-data-table {
width: 100%;
border-collapse: collapse;
margin: 18px 0;
font-size: 14px;
}.avp-data-table th {
background: var(–ink);
color: #fff;
padding: 14px 16px;
text-align: left;
font-weight: 600;
font-size: 12px;
text-transform: uppercase;
letter-spacing:.05em;
}.avp-data-table th:first-child { border-radius: 10px 0 0 0; }.avp-data-table th:last-child { border-radius: 0 10px 0 0; }.avp-data-table td {
padding: 14px 16px;
border-bottom: 1px solid #e8eef3;
}.avp-data-table tr:nth-child(even) { background: #f8fafc; }.avp-data-table tr:last-child td:first-child { border-radius: 0 0 0 10px; }.avp-data-table tr:last-child td:last-child { border-radius: 0 0 10px 0; }.avp-status-pass {
background: #10b981;
color: #fff;
padding: 4px 10px;
border-radius: 999px;
font-size: 11px;
font-weight: 700;
text-transform: uppercase;
}.avp-specs-table {
width: 100%;
border-collapse: collapse;
margin: 18px 0;
font-size: 14px;
}.avp-specs-table td {
padding: 12px 16px;
border-bottom: 1px solid #e8eef3;
}.avp-specs-table tr:nth-child(even) { background: #f8fafc; }.avp-specs-table td:first-child {
font-weight: 600;
color: var(–ink);
width: 40%;
}.avp-cards {
display: grid;
grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
gap: 16px;
margin: 18px 0;
}.avp-card {
background: linear-gradient(135deg, #f8fafc, #fff);
border: 1px solid #e2e8f0;
border-radius: 14px;
padding: 22px;
}.avp-card-icon {
font-size: 28px;
margin-bottom: 12px;
}.avp-card h4 {
font-size: 15px;
font-weight: 700;
color: var(–ink);
margin: 0 0 8px;
}.avp-card p {
font-size: 14px;
line-height: 1.6;
color: #64748b;
margin: 0;
}.avp-faq-category { margin-bottom: 24px; }.avp-faq-category h3 {
font-size: 14px;
font-weight: 700;
color: var(–c);
text-transform: uppercase;
letter-spacing:.08em;
margin: 0 0 14px;
padding-bottom: 8px;
border-bottom: 1px solid var(–line);
}.avp-faq-item {
background: #f8fafc;
border-radius: 12px;
padding: 18px;
margin-bottom: 12px;
}.avp-faq-item h4 {
font-size: 15px;
font-weight: 700;
color: var(–ink);
margin: 0 0 10px;
}.avp-faq-item p {
font-size: 14px;
line-height: 1.7;
color: #475569;
margin: 0;
}.avp-disclaimer {
background: linear-gradient(135deg, #fef3c7, #fef9e7);
border: 1px solid #f59e0b;
border-radius: 14px;
padding: 24px;
}.avp-disclaimer-icon { font-size: 32px; margin-bottom: 12px; }.avp-disclaimer-lead { font-size: 16px; color: #92400e; margin-bottom: 16px; }.avp-disclaimer h3 {
font-size: 14px;
font-weight: 700;
color: #92400e;
margin: 18px 0 10px;
}.avp-disclaimer ul { margin: 0 0 12px; padding-left: 20px; }.avp-disclaimer li {
font-size: 14px;
color: #a16207;
margin-bottom: 6px;
line-height: 1.5;
}.avp-disclaimer-footer {
font-size: 13px;
font-style: italic;
color: #a16207;
margin-top: 16px;
padding-top: 14px;
border-top: 1px solid rgba(245,158,11,.3);
}.avp-cta {
background: radial-gradient(800px 200px at 80% 120%, rgba(0,200,255,.15), transparent 60%), linear-gradient(135deg, var(–ink), var(–ink2));
border-radius: 20px;
padding: 32px;
text-align: center;
border: 1px solid var(–line);
}.avp-cta h2 {
font-size: 24px;
font-weight: 800;
color: #fff;
margin: 0 0 12px;
border: none;
padding: 0;
display: block;
}.avp-cta > p {
color: var(–muted);
font-size: 15px;
max-width: 600px;
margin: 0 auto 24px;
line-height: 1.6;
}.avp-cta-buttons {
display: flex;
justify-content: center;
flex-wrap: wrap;
gap: 12px;
margin-bottom: 24px;
}.avp-btn {
display: inline-flex;
align-items: center;
justify-content: center;
padding: 14px 28px;
border-radius: 10px;
font-size: 14px;
font-weight: 700;
text-decoration: none;
transition: all.2s;
cursor: pointer;
}.avp-btn-primary {
background: linear-gradient(135deg, var(–c), #00a8d6);
color: #fff;
box-shadow: 0 4px 20px rgba(0,200,255,.35);
}.avp-btn-primary:hover {
transform: translateY(-2px);
box-shadow: 0 6px 28px rgba(0,200,255,.45);
}.avp-btn-secondary {
background: rgba(255,255,255,.1);
color: #fff;
border: 1px solid rgba(255,255,255,.2);
}.avp-btn-secondary:hover { background: rgba(255,255,255,.18); }.avp-btn-tertiary { background: transparent; color: var(–c2); }.avp-btn-tertiary:hover { text-decoration: underline; }.avp-cta-trust {
display: flex;
justify-content: center;
flex-wrap: wrap;
gap: 10px;
}.avp-cta-trust.avp-trust-badge {
background: rgba(0,200,255,.12);
border: 1px solid var(–line);
border-radius: 999px;
padding: 8px 16px;
font-size: 12px;
font-weight: 600;
color: var(–c2);
}.avp-sequence-box {
padding: 1.5rem;
background: #f8fafc;
border-radius: 8px;
margin: 1.5rem 0;
font-family: monospace;
font-size: 0.8rem;
line-height: 1.8;
color: #0f172a;
word-wrap: break-word;
border: 1px solid #e2e8f0;
}.avp-component-label {
display: inline-block;
background: var(–ink);
color: var(–c);
font-size: 12px;
font-weight: 700;
letter-spacing:.08em;
text-transform: uppercase;
padding: 6px 14px;
border-radius: 8px;
margin: 28px 0 14px;
}.avp-component-label:first-of-type {
margin-top: 0;
}
@media (max-width: 640px) {.avp-product { padding: 0 12px 30px; margin: 20px auto; }.avp-hero { padding: 20px; border-radius: 20px; }.avp-hero h1 { font-size: 26px; }.avp-hero-stats { grid-template-columns: repeat(2, 1fr); }.avp-section { padding: 20px; border-radius: 16px; }.avp-data-table { font-size: 12px; }.avp-data-table th,.avp-data-table td { padding: 10px 12px; }.avp-cards { grid-template-columns: 1fr; }.avp-cta { padding: 24px 20px; }.avp-cta-buttons { flex-direction: column; }.avp-btn { width: 100%; }.avp-preorder-banner { flex-direction: column; text-align: center; }
}
TRIAD & Cagrilintide Blend
High-purity dual-peptide analytical reference blend — 10mg TRIAD + 2.5mg Cagrilintide (12.5mg total) in a single filler-free vial with comprehensive documentation for both components
Total Content
10mg + 2.5mg blend
Reta HPLC Purity
BVR verified
Cagri HPLC Purity
BVR verified
Fillers Added
No mannitol or bulking
Dual-Component Analytical Data
US Laboratory Supply
No Fillers or Bulking Agents
Product Overview
Celvaris Labs supplies this research-grade TRIAD & Cagrilintide dual-peptide blend as an analytical reference standard. Each vial contains 10mg TRIAD (CAS 2381089-83-2, synthetic 39-amino acid peptide with C20 diacid fatty acid modification, 4731.33 Da) and 2.5mg Cagrilintide (CAS 1415456-99-3, synthetic 39-amino acid acylated peptide with eicosanedioic acid modification and Cys3–Cys8 disulfide bridge, 4409.10 Da). Both components manufactured using solid-phase peptide synthesis (SPPS) with comprehensive analytical verification.
Primary applications: Reference standard for method development, analytical validation, peptide characterisation studies, and comparative quality control.
Documentation Included
- Batch Verification Report (BVR) – Complete batch-specific analytical data for both peptide components compiled by Celvaris Labs
- HPLC chromatography – TRIAD 99.37% purity / Cagrilintide 99.13% purity with retention time data
- Mass spectrometry (ESI-MS) – Molecular weight confirmation for both components (Reta: 4731.40 Da / Cagri: 4409.00 Da)
- Peptide content assay – TRIAD 92.19% / Cagrilintide 95.49% by nitrogen analysis
- Assay (HPLC) – TRIAD 99.45% / Cagrilintide 103.14% on anhydrous, salt-free basis
- Amino acid analysis – Complete composition verification for both peptides
- Karl Fischer water content – TRIAD 3.58% / Cagrilintide 2.96%
- Residual solvents results – All solvents below detection limits (both components)
- Microbial limits results – Total aerobic and yeast/mold counts compliant (both components)
- Bacterial endotoxins – Both components conform (<10EU/mg)
- Batch verification portal – QR code and online lookup system
Analytical Data (Batch Verification Report)
The following data represents typical batch results for each component. Your batch-specific values are available in your Batch Verification Report (BVR) via the verification portal.
Component 1 — TRIAD (10mg)
| Parameter | Result | Specification | Status |
|---|---|---|---|
| Purity (HPLC) | 99.37% | ≥98.0% | PASS |
| Peptide Content | 92.19% | ≥85.0% | PASS |
| Molecular Weight (ESI-MS) | 4731.40 Da | 4731.33 ±1.0 | PASS |
| Assay (HPLC) | 99.45% | 95.0-105.0% | PASS |
| Water Content (Karl Fischer) | 3.58% | ≤10.0% | PASS |
| pH (5.0mg/mL) | 7.25 | 6.0-8.0 | PASS |
| Solubility (water) | Conforms | ≥30mg/mL | PASS |
| Acetate Content | N.D. | ≤15.0% | PASS |
| TFA Content | N.D. | ≤0.5% | PASS |
| Sodium Salt | 1.79% | <5.0% | PASS |
| Bacterial Endotoxins | Conforms | <10EU/mg | PASS |
| Microbial Limits | Conforms | Per specification | PASS |
Component 2 — Cagrilintide (2.5mg)
| Parameter | Result | Specification | Status |
|---|---|---|---|
| Purity (HPLC) | 99.13% | ≥99.0% | PASS |
| Related Substances (Total) | 0.87% | ≤1.0% | PASS |
| Related Substances (Individual) | 0.39% | ≤0.5% | PASS |
| Peptide Content | 95.49% | ≥85.0% | PASS |
| Molecular Weight (ESI-MS) | 4409.00 Da | 4409.10 ±1.0 | PASS |
| Assay (HPLC) | 103.14% | 95.0-105.0% | PASS |
| Water Content (Karl Fischer) | 2.96% | ≤10.0% | PASS |
| Acetate Content | 4.62% | ≤12.0% | PASS |
| TFA Content | N.D. | ≤0.25% | PASS |
| High Molecular Protein | N.D. | ≤0.5% | PASS |
| Bacterial Endotoxins | Conforms | <10EU/mg | PASS |
| Microbial Limits | Conforms | Per specification | PASS |
Residual Solvents Results (Both Components)
| Solvent | TRIAD | Cagrilintide | Limit | Status |
|---|---|---|---|---|
| Acetonitrile | N.D. | N.D. | ≤410ppm | PASS |
| Methanol | N.D. | N.D. | ≤3000ppm | PASS |
| Methylene Chloride | N.D. | N.D. | ≤600ppm | PASS |
| N,N-Dimethylformamide | N.D. | N.D. | ≤880ppm | PASS |
| Isopropyl Ether | N.D. | N.D. | ≤5000ppm | PASS |
Amino Acid Analysis — Cagrilintide Component
| Amino Acid | Result | Specification | Status |
|---|---|---|---|
| His | 0.88 | 0.8-1.2 | PASS |
| Asp | 4.14 | 4.0-6.0 | PASS |
| Arg | 2.38 | 1.6-2.4 | PASS |
| Lys | 0.95 | 0.8-1.2 | PASS |
| Ile | 1.08 | 0.8-1.2 | PASS |
| Leu | 3.21 | 2.4-3.6 | PASS |
| Val | 1.08 | 0.8-1.2 | PASS |
| Thr | 4.71 | 4.0-6.0 | PASS |
| Phe | 2.39 | 1.6-2.4 | PASS |
| Ser | 3.02 | 2.4-3.6 | PASS |
| Ala | 2.82 | 2.4-3.6 | PASS |
| Gly | 2.19 | 1.6-2.4 | PASS |
| Glu | 2.95 | 2.4-3.6 | PASS |
| Pro | 4.18 | 3.2-4.8 | PASS |
Peptide Sequences
TRIAD
Cagrilintide
(Disulfide bridge: Cys3–Cys8)
| Molecular Identity | ||
| TRIAD | Cagrilintide | |
| Sequence Length | 39 amino acids + C20 diacid fatty acid modification | 39 amino acids + eicosanedioic acid modification + disulfide bridge |
| Molecular Formula | C₂₂₁H₃₄₂N₄₆O₆₈ | C₁₉₄H₃₁₂N₅₄O₅₉S₂ |
| Molecular Weight | 4731.33 Da (theoretical) / 4731.40 Da (observed) | 4409.10 Da (theoretical) / 4409.00 Da (observed) |
| CAS Number | 2381089-83-2 | 1415456-99-3 |
| Source | Synthetic peptide (SPPS) | |
Ordering Information
Package Contents
12.5mg total (10mg TRIAD + 2.5mg Cagrilintide) lyophilized powder blend in sealed glass vial with batch-specific labeling and QR verification code. No fillers, mannitol, or bulking agents added.
Batch Verification Report
Complete BVR with analytical data for both peptide components accessible via QR code scan, email link, or online verification portal at celvarislabs.com/verify.
US Express Shipping
Fast domestic express shipping nationwide. In stock — dispatched within 1-2 business days. If your order doesn’t arrive, we reship free , subject to our shipping policy.
Tier Pricing Available
Volume discounts for research facilities and repeat orders. Contact for institutional pricing and bulk quantities.
Quality & Verification
Batch Verification Report (BVR)
Every batch includes comprehensive analytical documentation for both blend components through Celvaris Labs’ verification system, presenting all manufacturer analytical data in a standardised format for full transparency.
Filler-Free Guarantee
Celvaris reference standards contain zero fillers. No mannitol, no bulking agents — just pure lyophilized peptide blend. The powder may appear smaller than competitors’ products because there’s nothing added to artificially increase volume.
Online Verification Portal
Instant batch verification via QR code or manual lookup. Access your batch-specific BVR anytime at celvarislabs.com/verify.
US Laboratory Supply
Celvaris Labs is a US supplier providing research-grade peptide reference materials to universities and biotech laboratories nationwide.
Complete Specifications
| Product Name | TRIAD & Cagrilintide Blend |
| SKU | CVL-B-RETACAG |
| Description | Dual-peptide analytical reference blend — two synthetic 39-amino acid acylated peptides with distinct fatty acid modifications |
| Blend Composition | 10mg TRIAD + 2.5mg Cagrilintide (12.5mg total per vial) |
| Physical Form | White to off-white lyophilized powder |
| Amount per Vial | 12.5mg total (net peptide content) |
TRIAD Component
| CAS Number | 2381089-83-2 |
| Molecular Formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular Weight | 4731.33 Da (ESI-MS verified: 4731.40 Da) |
| Sequence Length | 39 amino acids with C20 diacid fatty acid modification |
| Purity (HPLC) | 99.37% (typical, ≥98% specification) |
| Peptide Content | 92.19% (typical, ≥85% specification) |
| Assay (HPLC) | 99.45% (typical, 95-105% specification) |
| Water Content | 3.58% (typical, ≤10% specification) |
Cagrilintide Component
| CAS Number | 1415456-99-3 |
| Molecular Formula | C₁₉₄H₃₁₂N₅₄O₅₉S₂ |
| Molecular Weight | 4409.10 Da (ESI-MS verified: 4409.00 Da) |
| Sequence Length | 39 amino acids with eicosanedioic acid modification + Cys3–Cys8 disulfide bridge |
| Purity (HPLC) | 99.13% (typical, ≥99% specification) |
| Peptide Content | 95.49% (typical, ≥85% specification) |
| Assay (HPLC) | 103.14% (typical, 95-105% specification) |
| Water Content | 2.96% (typical, ≤10% specification) |
| Solubility | Both components soluble in water |
| Storage Conditions | Cool, dry place protected from light; -20°C for extended storage |
| Shelf Life | 24 months when stored properly (retest date on BVR) |
| Intended Use | Analytical Reference Standard / Research Use Only |
| Regulatory Status | Not for human or veterinary use; laboratory research only |
Frequently Asked Questions
Product Specifications
What is this blend?
This is a dual-peptide analytical reference blend containing two synthetic 39-amino acid acylated peptides: TRIAD (10mg, CAS 2381089-83-2, C₂₂₁H₃₄₂N₄₆O₆₈, 4731.33 Da) with C20 diacid fatty acid modification, and Cagrilintide (2.5mg, CAS 1415456-99-3, C₁₉₄H₃₁₂N₅₄O₅₉S₂, 4409.10 Da) with eicosanedioic acid modification and a Cys3–Cys8 disulfide bridge. This product is supplied strictly as an analytical reference standard for laboratory research.
What analytical data is provided?
Each batch includes a comprehensive Batch Verification Report (BVR) containing manufacturer analytical data for both peptide components: HPLC purity (Reta 99.37% / Cagri 99.13%), peptide content (Reta 92.19% / Cagri 95.49%), ESI-MS molecular weight confirmation, assay results (Reta 99.45% / Cagri 103.14%), amino acid analysis, Karl Fischer water content, pH measurement, solubility confirmation, residual solvents results, bacterial endotoxins, and microbial limits results. Access via QR code or online verification portal.
How do I verify my batch?
Three methods: (1) Scan QR code on product label, (2) Click verification link in order confirmation email, (3) Visit celvarislabs.com/verify and enter batch ID. All provide instant access to your batch-specific Batch Verification Report with complete analytical data for both blend components.
Why does the powder look smaller than other suppliers?
Celvaris reference standards are filler-free. Many suppliers add mannitol or other bulking agents to make the powder appear larger in the vial. Our vials contain only pure lyophilized peptide — nothing else. Less visible powder actually means a purer product with no unnecessary additives. Learn more at celvarislabs.com/peptide-fillers-explained.
What is the shelf life?
Typically 24 months when stored in sealed vial at -20°C or below, protected from light and moisture. Specific retest date listed on Batch Verification Report.
What are the CAS numbers?
TRIAD: CAS 2381089-83-2 (MW 4731.33 Da, C₂₂₁H₃₄₂N₄₆O₆₈). Cagrilintide: CAS 1415456-99-3 (MW 4409.10 Da, C₁₉₄H₃₁₂N₅₄O₅₉S₂). Both confirmed in the Batch Verification Report.
Is this a pre-order product?
No. This blend is in stock and dispatches within 1-2 business days of your order.
Regulatory & Compliance
What is the regulatory status?
Both TRIAD and Cagrilintide are supplied for research use only. They are NOT approved for human consumption, therapeutic use, veterinary applications, or diagnostic procedures. Purchasers are responsible for ensuring compliance with all applicable regulations.
Does Celvaris provide research protocols or application guidance?
No. Celvaris supplies analytical reference materials only. We do not provide reconstitution protocols, application methods, dosing information, or research design guidance. Researchers must develop protocols based on scientific literature and appropriate oversight.
Regulatory Disclaimer – Analytical Reference Material
TRIAD & Cagrilintide Blend is supplied as an analytical reference standard for research use only.
NOT for:
- Human consumption, administration, or therapeutic use
- Veterinary or animal health applications
- Diagnostic procedures
- Clinical trials or medical research involving human subjects (without appropriate approvals)
- Food, cosmetic, or dietary supplement applications
- Personal or consumer use of any kind
Purchaser Responsibilities:
- Verify compliance with all applicable federal, state, and local regulations
- Maintain proper laboratory safety and handling procedures
- Ensure appropriate storage, documentation, and chain of custody
- Use only for legitimate analytical/research purposes as intended
Celvaris Labs Does NOT Provide:
- Medical, therapeutic, or health-related advice
- Dosing recommendations or administration protocols
- Reconstitution instructions or methods
- Research design or experimental methodologies
Pre-Order TRIAD & Cagrilintide Blend
High-purity dual-peptide analytical reference blend (12.5mg total). Every order includes complete Batch Verification Report (BVR) with analytical data for both components, batch verification portal access, filler-free guarantee, and US domestic express shipping with free reship guarantee.
Reviews
There are no reviews yet.